Program Leadership


Program Leadership

Tonja Green, Program Director

Tonja Green, joined San Jose State University in July, 2008 as Director of the newly established MS in Medical Product Development Management program. As Director, she successfully built the operational aspects of the program and is responsible for administration of the program, including program admissions, student advisement, faculty and guest speaker recruitment, industry collaborations, developing and teaching a core series of courses, overseeing curriculum content and program direction.

Ms. Green has a breadth of clinical research experience spanning therapeutic areas of cardiology, peripheral/neurovascular (stents, catheters, etc), oncology, endocrinology, rheumatology, gastroenterology, neurology, hematology, psychiatry, infectious disease, and immunology. Ms. Green has also held multiple hands-on and leadership clinical research positions in medical device, diagnostics, biologic, and pharmaceutical companies including Syntex Pharmaceuticals, Protein Design Labs, Aryx Therapeutics, Arete Therapeutics, and Therasense (now Abbott Diabetes Care). Ms. Green gained early career experience within the hospital clinical setting including Stanford University Medical Center and is an alumna of SJSU. She currently serves as a clinical consultant and advisor to biopharmaceutical, device, and diagnostic companies.

Dr. Stephan Crothers, Director of Biomedical Initiatives

Dr. Stephan Crothers, Ph.D., MBA holds a doctorate in Medical Science and Biochemistry from Boston University School of Medicine and a Master of Business Administration from the University of Southern California. Prior to joining the San Jose State University's College of a Science in 2002, Dr. Crothers pursued a 25-year career in the pharmaceutical, medical diagnostics, and life science research products industries, most recently as vice president of product development at Entelos, an "in silico R&D" company.

In addition to positions of increasing responsibility at SmithKline Pharmaceuticals, Syntex's medical diagnostics company SYVA, and Molecular Devices (analytical instrumentation), he was a co-founder of two startup companies, PanAb Laboratories and TransMed Biotech. Dr. Crothers is best known in his role of private consultant in the management of product research and early stage development where his expertise is in the strategic focusing of R&D resources.

Dr. Crothers is responsible for directing the College of Science at SJSU towards the establishment of new degree programs to prepare students for employment in areas of emerging biomedical technologies and their commercial development. He has led the effort of developing the Master of Science in Medical Product Development and Clinical Research Management degree program. Dr. Crothers also participated with the City of San Jose Redevelopment Agency and the San Jose State University Foundation in the establishment of a Biotechnology Incubator and Innovation Center. He serves as a "CEO mentor" at the Innovation Center.

Advisory Board

Jayne M. Dito
Consultant, Biotech and Pharmaceutical Industry

Ms. Jayne Dito has over 30 years experience in the biotech and pharmaceutical industry, most recently as COO for Clinimetrics Research. Prior to joining Clinimetrics, she served in management positions at Triton Bioscience and Matrix Pharmaceutical. Jayne has a B.S. in Health Science, graduating from San Jose State University with honors. She is also a graduate of St. Mary's College of Nursing in San Francisco. Jayne is currently working as a consultant in Clinical Development, Clinical Operations, and Project Management in the biotech-pharmaceutical industry.

Kevin Dwyer
Managing Partner, VP, Business Development
Pacific BioDevelopment, LLC

Mr. Dwyer has over 30 years experience in drug development for the biotech and pharmaceutical industries. He is a co-founder and Managing Partner for Pacific BioDevelopment, LLC (PBD) and currently serves as the VP of Business Development. As Managing Partner, Mr. Dwyer insures that PBD provides the highest quality, integrated drug development strategies for its clients. As VP of Development, he provides PBD's clients with high-level strategic development plans, and assistance in raising funds, as well as due diligence for licensing compounds and/or M&A.

Prior to becoming the VP of Business Development, Mr. Dwyer built the Regulatory Affairs department at PBD. He has over 30 years of experience at companies such as Monsanto, Genentech and PBD, more than 20 years of which have been in regulatory affairs. His experience also enables him to develop novel and effective regulatory and overall drug development strategies for U.S. and international clients. He holds a B.A. in Biology from St. Louis University, St. Louis, MO.

Stan Fink, Ph.D.
Divisional Vice President
Clinical and Regulatory Affairs
Abbott Vascular

Abbott Vascular is a division of Abbott Laboratories, one of the world's largest health care companies. The company, which ranks No. 96 on the FORTUNE 500, has more then 68,000 employees worldwide with customers in more then 130 countries. Abbott is headquartered in north suburban Chicago. Dr. Fink joined Abbott in November of 2005 as the Divisional VP, Clinical Affairs, and assumed his current role in 2007.

Prior to joining Abbott, Stan was with Guidant's Vascular Intervention Division for 8 years as Director of Clinical Research. Prior to Guidant, Stan was with Biomedical Sensors, Pfizer Hospital Products Group, where he held the positions of Director, Clinical Research and Development, Program Manager, R&D and Director, R&D. Stan also spent three years at NASA conducting research in cardiovascular physiology as applied to manned space flight.

Stan earned a bachelor's degree from the City University of New York and a master's degree from the University of California, Berkeley in Chemical Engineering. He also holds a Ph.D. in the Mechanical Engineering, Bio-Engineering Program from the University of California, Berkeley.

Mark A. McCamish, M.D., Ph.D.
Global Head Biopharmaceutical Development
Sandoz International

Dr. McCamish is responsible for worldwide drug development activities focusing on developing monoclonal antibodies for oncology and select immunologic diseases. From 2003 to 2007, he served as the Chief Medical Officer and VP of Clinical Development at Perlegen Sciences responsible for co-development of drugs linked to predictive genetic diagnostic tests. Previously, he was Global Development Leader at Amgen, Inc., where he served in several clinical management positions involving development of biologics and drugs in diabetes, obesity, anemia, prostate cancer, rheumatoid arthritis, and heart failure.

Prior to Amgen, Dr. McCamish served at Abbott Laboratories for 7 years, conducting international clinical research developing medical devices and medical nutritional products in multiple therapeutic areas. He continued to hold an academic appointment treating patients as Clinical Associate Professor in the Department of Internal Medicine, Division of Endocrinology at Ohio State University.

Before Abbott, he held various clinical, academic and research responsibilities in the Department of Internal Medicine at the University of California at Davis. He is Board Certified in Internal Medicine as well as Clinical Nutrition and Metabolism. Dr. McCamish has published broadly and has degrees in Exercise Physiology, Ergonomics, Human Nutrition and Medicine.

Marjorie McCray
Clinical Mgr
Gilead

Mary Poppenheimer
Drug Safety & Risk Management, VP Global Sales of Quintiles, Inc.

Ms. Poppenheimer's 20 years of drug-development experience is comprehensive, including nonclinical, clinical, and commercial. She has 10 years of experience managing entire drug development programs in the pharmaceutical and biotechnology industries. Her 8 years sales experience spans all research phases, therapeutic areas, and service lines (preclinical, clinical, & post marketing) and includes personnel management, site management, and product-specific proposal development management (Ph V Global Proposals). She also has 2 years experience working as a research coordinator in a private medical practice administering clinical trials.

Mary has a B.A. in Biology from SUNY Binghamton and is a member of the Board of Directors, Cardinal Newman High School.

Lecia Shaffer
Co-Founder
Nextrials

Edward (Ted) Spack, Ph.D.
Senior Director of Business Development
Biosciences Division of SRI International (Menlo Park, CA)

Dr.Spack's focus at SRI is partnering a pipeline of preclinical drug candidates. He works to advance their clinical development, to generate future royalties that will support further research, and to establish novel models for translational R&D. Ted also manages the PharmaSTART program, a consortium between SRI and Stanford, UC Berkeley, UC San Diego, and UC San Francisco established to translate academic discoveries to the clinic. Ted has over 25 years of academic and biotech experience in basic research and drug development.

Ted was trained in cellular immunology through doctoral studies at The Johns Hopkins University and a post-doctoral fellowship at Stanford University. In the following 13 years, he worked in three Bay Area biotech companies, leading applied research in a wide range of diseases, including autoimmunity, infectious disease, and cancer. He directed internal projects and academic collaborations using a wide range of therapeutic approaches, including recombinant biologics, humanized monoclonal antibodies, small molecules, and gene therapy.

Ted served on the Board of Directors of the National Myasthenia Gravis Foundation and is currently on the scientific advisory boards of the Dystonia Medical Research Foundation and the California Myasthenia Gravis Organization, and consults on translational development programs for the Michael J. Fox Foundation for Parkinson's Research and the Alzheimer's Drug Discovery Foundation.

Barry M. Sherman, M.D.
Executive Vice President Development
BiPar Sciences, Inc.

Dr. Sherman has over 30 years experience in academic and pharmaceutical biomedical research. He served as President and CEO of Anergen Inc., a founder of Pain Therapeutics, Inc., and as Genentech's first Senior Vice President and Chief Medical Officer. He has also been a Board member and consultant to several biotechnology and pharmaceutical companies. Prior to joining Genentech in 1985, Dr. Sherman was Professor of Medicine and Endocrinology at the University of Iowa College of Medicine, where he served as Associate Chairman of the Department of Internal Medicine and Director of the NIH-sponsored Clinical Research Center.

Dr. Sherman is a graduate of the University of Michigan in Ann Arbor, where he received both his AB and MD degrees with honors. He completed his clinical and research training at the Albert Einstein College of Medicine in New York, the National Institutes of Health in Bethesda, Maryland, and at the University of Michigan. He has contributed more than 125 publications to the scientific literature including articles, chapters and books resulting from his NIH-funded laboratory and human investigation and results from the study of new pharmaceuticals.